Skip to content

#Ibogaine

19 NovThu
  1. Marijuana Moment (psychedelics policy only)42

    US House veterans committee holds hearing on psychedelic therapies for military veterans

    A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.

17 NovTue
  1. Marijuana Moment (psychedelics policy only)40

    US House Veterans' Affairs health subcommittee to hold hearing on psychedelic-assisted therapies for veterans

    The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.

14 NovSat
  1. The Microdose (UC Berkeley BCSP)62

    FDA said to end priority voucher program as Compass Pathways files psilocybin application

    Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.

13 NovFri
  1. Psychedelic Alpha48

    HHS taps Mark Cuban's company to develop ibogaine for PTSD and commits $20M for real-world evidence network

    The U.S. Department of Health and Human Services said it will tap Mark Cuban's company to develop ibogaine for post-traumatic stress disorder and commit $20 million to a real-world evidence network. HHS Secretary RFK Jr. gave the update at a press conference, where VA Senior Advisor Andrew Gradison stood in for VA Secretary Doug Collins.

29 OctThu
  1. Lucid News58

    US federal health officials outline pre-approval groundwork for psychedelic medicines

    Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.

5 OctMon
  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.

23 SepWed
18 SepFri